5-(4-methoxyphenyl)-3-phenoxycarbonyl-aminopyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-methoxyphenyl)-3-phenoxycarbonyl-aminopyrazole
• 英文别名: 5-(4-Methoxyphenyl)-3-phenoxycarbonylaminopyrazole；phenyl N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbamate
• 化学式: C₁₇H₁₅N₃O₃
• 分子量: 309.324
• InChiKey: YFQAVEHQFPRUNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  76.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[2-(哌嗪-1-基)]甲基磺酰胺盐酸盐 、 5-(4-methoxyphenyl)-3-phenoxycarbonyl-aminopyrazole 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.0h， 以50 mg的产率得到
  参考文献：
  名称：

  Novel potent neuropeptide Y Y5 receptor antagonists: Synthesis and structure–activity relationships of phenylpiperazine derivatives

  摘要：

  A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities. The benzindane portion of 2 was replaced by I-phenylpiperazine, resulting in novel urea derivative X Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.07.023
• 作为产物：
  描述：

  4-甲氧基苯甲酸甲酯 在 吡啶 、 一水合肼 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 7.0h， 生成 5-(4-methoxyphenyl)-3-phenoxycarbonyl-aminopyrazole
  参考文献：
  名称：

  Novel potent neuropeptide Y Y5 receptor antagonists: Synthesis and structure–activity relationships of phenylpiperazine derivatives

  摘要：

  A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities. The benzindane portion of 2 was replaced by I-phenylpiperazine, resulting in novel urea derivative X Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.07.023

文献信息

• Urea derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US06043246A1

  公开（公告）日：2000-03-28

  The present invention relates to a compound represented by the general formula [I]: ##STR1## wherein A represents a nitrogen atom or a group represented by C--R.sup.5 ; Ar.sup.1 represents an aryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl and lower haloalkyl groups; Ar.sup.2 represents an aryl or heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aryl groups; R.sup.1 represents a hydrogen atom, a lower alkyl group or a bond formed by linking to R.sup.5 ; R.sup.2 represents a hydrogen atom or a lower alkyl group; R.sup.3 and R.sup.4 may be the same or different and each represents a hydrogen atom or a lower alkyl group, or R.sup.3 and R.sup.4 are linked to each other to form an alkylene group containing 2 to 4 carbon atoms which may have a lower alkyl group; and R.sup.5 represents a hydrogen atom or a hydroxyl, lower alkyl or lower alkoxy group or a bond formed by linking to R.sup.1, or its salt, a process for its preparation and an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.

  本发明涉及一种由通式[I]表示的化合物：##STR1## 其中A代表氮原子或由C-R.sup.5表示的基团; Ar.sup.1代表芳基基团，可以具有从卤原子和较低的烷基和卤代烷基组成的取代基; Ar.sup.2代表芳基或杂环芳基，可以具有从卤原子和较低的烷基，较低的烯基，较低的卤代烷基，较低的烷氧基，较低的烷硫基，较低的烷基氨基，较低的二烷基氨基和芳基组成的取代基; R.sup.1代表氢原子，较低的烷基或通过与R.sup.5连接形成的键; R.sup.2代表氢原子或较低的烷基; R.sup.3和R.sup.4可以相同也可以不同，每个代表氢原子或较低的烷基，或R.sup.3和R.sup.4连接在一起形成含有2到4个碳原子的烷基，可以具有较低的烷基; R.sup.5代表氢原子或羟基，较低的烷基或较低的烷氧基，或通过与R.sup.1连接形成的键，或其盐，其制备方法以及作为活性成分的治疗暴食症、肥胖症或糖尿病的药剂。
• NOVEL UREA DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0955293A1

  公开（公告）日：1999-11-10

  The present invention relates to a compound represented by the general formula [I]: wherein A represents a nitrogen atom or a group represented by C-R5; Ar1 represents an aryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl and lower haloalkyl groups; Ar2 represents an aryl or heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aryl groups; R1 represents a hydrogen atom, a lower alkyl group or a bond formed by linking to R5; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and each represents a hydrogen atom or a lower alkyl group, or R3 and R4 are linked to each other to form an alkylene group containing 2 to 4 carbon atoms which may have a lower alkyl group; and R5 represents a hydrogen atom or a hydroxyl, lower alkyl or lower alkoxy group or a bond formed by linking to R1, or its salt, a process for its preparation and an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.

  本发明涉及通式[I]所代表的化合物： 其中A代表氮原子或由C-R5代表的基团；Ar1代表芳基，其取代基可选自卤素原子和低级烷基及低级卤代烷基组成的组；Ar2代表芳基或杂芳基，其取代基可选自卤素原子和低级烷基、低级烯基、低级卤代烷基、低级烷氧基、低级烷硫基、低级烷基氨基、低级二烷基氨基和芳基组成的组；R1 代表氢原子、低级烷基或与 R5 连接形成的键；R2 代表氢原子或低级烷基；R3 和 R4 可以相同或不同，且各自代表氢原子或低级烷基，或 R3 和 R4 相互连接形成含 2 至 4 个碳原子的亚烷基，该亚烷基可能具有低级烷基；以及 R5 代表氢原子或羟基、低级烷基或低级烷氧基或与 R1 连接形成的键、 或其盐类，其制备方法和治疗贪食症、肥胖症或糖尿病的制剂，其活性成分包括它。
• UREA DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0955293B1

  公开（公告）日：2003-03-19
• US6043246A
  申请人：——

  公开号：US6043246A

  公开（公告）日：2000-03-28